On Feb. 23, the WHO told national vaccine regulatory agencies and pharmaceutical companies its recommendations for the viral composition of next season’s influenza vaccines.
A trivalent vaccine protects against three strains of the flu, including two influenza A strains and one influenza B strain. Last year, the WHO recommended quadrivalent shots.
For egg-based vaccines — which the CDC recently OK’d for people with egg allergies — the WHO suggests they target an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell-culture or recombinant-based vaccines are recommended to contain an A/Wisconsin/67/2022 (H1N1)pdm09-like virus, an A/Massachusetts/18/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Quadrivalent vaccines for the 2024-25 Northern Hemisphere flu season are encouraged to also include a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
